Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03168256
Other study ID # CF101-301PS
Secondary ID
Status Completed
Phase Phase 3
First received
Last updated
Start date September 15, 2018
Est. completion date April 27, 2022

Study information

Verified date June 2022
Source Can-Fite BioPharma
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This trial will test the hypothesis that the administration of CF101, a novel anti-inflammatory agent, to patients with moderate to severe plaque psoriasis will relieve signs and symptoms of the disease. CF101 effect will be in comparison to apremilast in this study population


Description:

This is a multicenter, randomized, double-blind, placebo- and active-controlled, study in adult males and females, aged 18 to 80 years, inclusive, with a diagnosis of moderate-to-severe chronic plaque psoriasis. Eligible subjects will be randomly assigned to CF101 2 mg, 3 mg, matching apremilast 30 mg BID, or matching placebo, in a 3:3:3:2 ratio. Blinding will be maintained using a double-dummy technique. Medication will be taken orally BID for 32 weeks in a double-blinded fashion, with the option to continue treatment through an Extension Period to 48 weeks. Subjects initially assigned to the placebo group will be re-randomized at Week 16 to either CF101 2 mg, CF101 3 mg, or apremilast (with appropriate dose titration) in a 1:1:1 ratio and treated through Week 32, while subjects originally assigned to 1 of the active treatment groups will remain on that treatment through Week 32. The primary efficacy endpoint will be assessed at Weeks 16 and 32; at Week 32, all subjects will be offered the opportunity to remain on their assigned blinded drug through Week 48 (ie, the Extension Period of Weeks 33-48). Disease will be assessed using PASI , static PGA , the percentage of BSA involved, and PDI. Subjects will return for assessments and a new supply of study medication at Weeks 4, 8, 12, 16, 20, 24, and 28, and for final study assessments at Week 32. For those subjects continuing into the Extension Period, efficacy and safety assessments will also occur at Weeks 36, 40, 44, and 48. PK will be assessed in a subgroup of approximately 120 subjects at Weeks 0, 8, 16, 24 and 32. PK will be assessed through sparse sampling. Assessment of whole blood A3AR expression levels will occur at Screening, Week 16, and Week 32.


Recruitment information / eligibility

Status Completed
Enrollment 528
Est. completion date April 27, 2022
Est. primary completion date January 6, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: 1. Male or female, 18 to 80 years of age, inclusive; 2. Diagnosis of moderate-to-severe chronic plaque-type psoriasis with BSA involvement =10%, as judged by the Investigator; 3. PASI score =12 (Appendix 3) 4. Static PGA =3 (Appendix 2) 5. Candidate for systemic treatment or phototherapy for psoriasis; 6. Duration of psoriasis of at least 6 months; 7. Elevated whole blood A3AR expression level, defined as = 1.5-fold over a predetermined normal population standard at Screening; 8. Females of child-bearing potential must have a negative serum pregnancy test at screening; 9. Females of child-bearing potential must be willing to use 2 methods of contraception deemed adequate by the Investigator (for example, oral contraceptive pills plus a barrier method) to be eligible for, and continue participation in, the study; 10. Ability to complete the study in compliance with the protocol; and 11. Ability to understand and provide written informed consent. Exclusion Criteria: 1. Psoriasis limited to erythrodermic, guttate, palmar, plantar, or generalized pustular psoriasis in the absence of plaque psoriasis; 2. Prior treatment with apremilast within 4 weeks prior to the Baseline visit, or contraindication to apremilast; 3. Treatment with systemic retinoids, corticosteroids, tofacitinib, or immunosuppressive agents (e.g., methotrexate, cyclosporine) within 4 weeks of the Baseline visit; 4. Treatment with a biological agent (etanercept, adalimumab, efalizumab, infliximab, ustekinumab, alefacept, secukinumab, or others, including investigational agents) within a period of time equal to 5 times its circulating half-life, or 30 days, whichever is longer, prior to the Baseline visit; 5. Treatment with high potency topical dermatological corticosteroids (Class I-III in US, Class III-IV in Europe), Vitamin D analogs, keratolytics, or coal tar (other than on the scalp, palms, groin, and/or soles) within 2 weeks of the Baseline visit; 6. Ultraviolet or Dead Sea therapy within 4 weeks of the Baseline visit, or anticipated need for either of these therapies during the study period; 7. Treatment with lithium, hydroxychloroquine or chloroquine within 2 weeks of the Baseline visit, or anticipated need for such drugs during the study period, unless dose has been stable for 3 months prior to the Screening visit and will remain stable throughout the trial; 8. Serum creatinine level greater than 1.5 times the laboratory's upper limit of normal at Screening; 9. Liver aminotransferase levels greater than 1.5 times the laboratory's upper limit of normal at Screening; 10. Electrocardiogram (ECG) at Screening shows abnormalities which, in the judgment of the Investigator, are clinically significant and could, in the judgment of the Principal Investigator, compromise subject safety; 11. Active gastrointestinal disease which could interfere with the absorption of oral medication; 12. Pregnancy, planned pregnancy, lactation, or inadequate contraception as judged by the Investigator; 13. Active drug or alcohol dependence; 14. History of depression or suicidal ideation within the past year; 15. Concomitant use of strong cytochrome P450 inducers, eg, rifampin, phenobarbital, phenytoin, carbamazepine; 16. Previous participation in a CF101 clinical trial; 17. Significant acute or chronic medical or psychiatric illness that, in the judgment of the Investigator, could compromise subject safety, limit the subject's ability to complete the study, and/or compromise the objectives of the study; 18. Participation in another investigational drug or vaccine trial concurrently or within 30 days prior to the Screening visit.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
CF101 2mg
CF101 tablets, 2mg BID for 16 weeks
CF101 3mg
CF101 tablets, 3mg BID for 16 weeks
Apremilast 30mg
Apremilast tablets, 30mg BID for 16 weeks
Placebo Oral Tablet
Placebo tablets, BID for 16 weeks

Locations

Country Name City State
Bosnia and Herzegovina Clinical Centre of Republika Srpska Banja Luka
Bosnia and Herzegovina University Clinical Centre Mostar Mostar
Bosnia and Herzegovina Clinical Centre of Sarajevo University Sarajevo
Bulgaria "Multiprofile Hospital for Active Treatment - Pazardzhik" Pazardzhik
Bulgaria "MHAT"Rahila Angelova"AD, Department of Skin and Venereal Diseases Pernik
Bulgaria "University Multiprofile Hospital for Active Treatment - D-r Georgi Stranski" - EAD, Pleven, Clinic of Skin and Venereal Diseases Pleven
Bulgaria "Diagnostic-Consultative Aleksandrovska" EOOD Sofia
Bulgaria "Diagnostic-Consultative Centre XX - Sofia" EOOD Sofia
Bulgaria Ambulatory for Specialized Medical Help - Group Practice Dermatology - Clinic EuroDerma" OOD Sofia
Canada K. Papp Clinical Research Waterloo
Croatia Clinical Hospital Center Rijeka Rijeka
Croatia Sestre milosrdnice University Hospital Center Zagreb
Israel Rambam Medical Center Haifa
Moldova, Republic of Institutul de Cardiologie Chisinau
Moldova, Republic of Spitalul Clinic Municipal Nr. 3 "Sfanta Treime" Chisinau
Moldova, Republic of Spitalul Clinic Republican Chisinau
Poland Centrum Uslug Medycznych MaxMed Bochnia
Poland Gdanskim Centrum Zdrowia Gdansk
Poland All-MED Centrum Medyczne Lódz
Poland Miejski Szpital Zespolony Klinika Dermatologii Chorób Przenoszonych Droga Plciowa i Immunologii klinicznej Olsztyn
Poland Lubelskie Centrum Diagnostyczne Swidnik
Poland ETG Zamosc, ul. Szczebrzeska 11i Zamosc
Romania Centrul Medical de Diagnostic si Tratament Ambulator Neomed SRL Brasov
Romania SC PELICAN Impex SRL Oradea
Romania Spitalul Clinic Jude?ean de Urgen?a Sibiu Sibiu
Serbia Clinical Centre of Serbia Belgrade
Serbia Clinical Centre Nis Niš
Serbia Military Hospital Nis Niš
Serbia General Hospital Sremska Mitrovica Sremska Mitrovica
Serbia General Hospital Zajecar Zajecar

Sponsors (1)

Lead Sponsor Collaborator
Can-Fite BioPharma

Countries where clinical trial is conducted

Bosnia and Herzegovina,  Bulgaria,  Canada,  Croatia,  Israel,  Moldova, Republic of,  Poland,  Romania,  Serbia, 

Outcome

Type Measure Description Time frame Safety issue
Primary Psoriasis Area and Severity Index (PASI) score response of =75% (PASI 75) at Week 16 Evaluate the efficacy of oral CF101 2 mg or 3 mg twice daily (BID) in patients with moderate-to-severe plaque psoriasis, compared with placebo, as determined by the proportion of subjects who achieve a Psoriasis Area and Severity Index (PASI) score response of =75% (PASI 75) at Week 16 (superiority) 16 weeks
Primary Adverse event profile in this patient popluation Nature, incidence and severity of treatment-emergent adverse events 16 weeks
Secondary Psoriasis Area and Severity Index (PASI) score response of =50% (PASI 50) at Week 16 Evaluate the efficacy of oral piclidenoson 2 mg or 3 mg BID, compared with placebo, as determined by the proportion of subjects who achieve PASI 50 at Week 16 (superiority); 16 weeks
Secondary Physician Global Assessment (PGA) Evaluate the efficacy of oral piclidenoson 2 mg or 3 mg BID, compared with placebo, as determined by the proportion of subjects who achieve PGA score of 0 or 1 at Week 16; 16 weeks
Secondary Psoriasis Disability Index (PDI) Evaluate the efficacy of oral piclidenoson 2 mg or 3 mg BID, compared with placebo, as determined by the proportion of subjects who achieve improvement on the PDI at Week 16; 16 weeks
Secondary CF101 PASI 75 compare to apremilast Evaluate the efficacy of oral piclidenoson 2 mg or 3 mg BID, compared with apremilast, as determined by the proportion of subjects who achieve PASI 75 at Weeks 16 and 32; weeks 16-32
Secondary CF101 PGA score compare to apremilast Evaluate the efficacy of oral piclidenoson 2 mg or 3 mg BID, compared with apremilast, as determined by the proportion of subjects who achieve PGA score of 0 or 1, at Weeks 16 and 32; weeks 16-32
Secondary CF101 PASI 50 compare to apremilast Evaluate the efficacy of oral piclidenoson 2 mg or 3 mg BID, compared with apremilast, as determined by the proportion of subjects who achieve PASI 50 at Weeks 16 and 32; weeks 16-32
Secondary CF101 PDI improvement compare to apremilast Evaluate the efficacy of oral piclidenoson 2 mg or 3 mg BID, compared with apremilast, as determined by the proportion of subjects who achieve an improvement in PDI at Weeks 16 and 32; weeks 16-32
Secondary Apremilast PASI 75 compare to placebo Establish assay sensitivity within this trial by comparing the efficacy of apremilast 30 mg BID with that of placebo tablets BID, as determined by the proportion of subjects who achieve PASI 75, PGA score of 0 or 1, PASI 50, and improvement in PDI at Week 16 (superiority); weeks 16-32
Secondary Apremilast PGA compare to placebo Establish assay sensitivity within this trial by comparing the efficacy of apremilast 30 mg BID with that of placebo tablets BID, as determined by the proportion of subjects who achieve PGA score of 0 or 1 at Week 16; weeks 16-32
Secondary Apremilast PASI 50 compare to placebo Establish assay sensitivity within this trial by comparing the efficacy of apremilast 30 mg BID with that of placebo tablets BID, as determined by the proportion of subjects who achieve PASI 50 at Week 16; weeks 16-32
Secondary Apremilast PDI compare to placebo Establish assay sensitivity within this trial by comparing the efficacy of apremilast 30 mg BID with that of placebo tablets BID, as determined by the proportion of subjects who achieve improvement in PDI at Week 16; 16 weeks
Secondary Adverse event profile of piclidenoson through the Extension Period of up to 48 weeks of treatment Nature, incidence, and severity of treatment-emergent adverse events 48 weeks
Secondary Efficacy of piclidenoson, as determined by changes in PASI score, through the Extension Period of up to 48 weeks of treatment The proportion of subjects who achieve a Psoriasis Area and Severity Index (PASI) score response of =75% (PASI 75) at Week 48 48 weeks
Secondary Determine pharmacokinetics (PK) of piclidenoson under the circumstances of this trial using sparse sampling Serum concentration of piclidenoson 48 weeks
Secondary Evaluate the relationship between pre-treatment whole blood A3 adenosine receptor (A3AR) expression levels and response to piclidenoson treatment. Explore the relationship between white blood cell (WBC) adenosine A3 receptor (A3AR) expression and treatment response, by taking WBC sample at baseline 16 weeks
See also
  Status Clinical Trial Phase
Completed NCT01194219 - Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis Phase 3
Recruiting NCT06030076 - A Study to Assess the Effects of Switching From a Biologic Treatment to Tildrakizumab Using Patient-reported Outcomes in Adult Participants With Moderate to Severe Plaque Psoriasis
Completed NCT04263610 - Efficacy and Safety of Tildrakizumab in Participants With Moderate-to-Severe Chronic Plaque Psoriasis Who Are Non-Responders to Dimethyl Fumarate Therapy Phase 4
Completed NCT02601469 - Study to Assess the Potential for Adrenal Suppression Following Treatment With DSXS in Patients With Plaque Psoriasis Phase 2
Completed NCT05600036 - A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Plaque Psoriasis Phase 2
Completed NCT05375955 - A Study to Learn About The Study Medicine (PF-07038124) In Patients With Mild To Moderate Atopic Dermatitis Or Mild To Severe Plaque Psoriasis. Phase 2
Completed NCT03614078 - A Study of PRCL-02 in Moderate to Severe Chronic Plaque Psoriasis Phase 2
Not yet recruiting NCT05036889 - A 16-week Randomized Evaluation of the Impact of Mind.Px Application on Response to Biologic Treatment in Patients Suffering From Plaque Psoriasis Through Clinical Utility and Health Outcomes. N/A
Completed NCT04603027 - A Phase 2 Study Investigating the Effect of EDP1815 in the Treatment of Mild to Moderate Plaque Psoriasis Phase 2
Completed NCT03638258 - The Safety, Efficacy and Pharmacokinetics of ARQ-151 Cream in Subjects With Chronic Plaque Psoriasis Phase 2
Completed NCT02881346 - Efficacy and Tolerability of Enstilar® in Daily Practice
Recruiting NCT02611349 - Study to Evaluate the Long-Term Safety of IDP-118 Lotion in the Treatment of Plaque Psoriasis Phase 3
Completed NCT02251678 - Evaluate the Effect of Elimune Capsules Phase 1
Completed NCT01987843 - Dose-finding Study of MT-1303 in Subjects With Moderate to Severe Chronic Plaque Psoriasis Phase 2
Terminated NCT01708629 - Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects Phase 3
Completed NCT01230138 - Pivotal Efficacy and Safety Registration Trial of FP187 in Moderate to Severe Plaque Psoriasis Phase 2
Withdrawn NCT00747032 - To Demonstrate the Superior Efficacy of NYC 0462 Ointment Over That of the Placebo in the Treatment of Plaque Psoriasis Phase 3
Completed NCT00581100 - Effects of Etanercept on Nail Psoriasis and Plaque Psoriasis Phase 4
Suspended NCT01228656 - Effectiveness of Association Mometasone Furoate 0.1% and Salicylic Acid 5% Compared With Mometasone Furoate Phase 2
Completed NCT00540618 - A Phase II Study of MEDI-507, Administered by Injection to Adults With Psoriasis Phase 2